Everest Medicines' (HKG:1952) kidney drug Nefecon, indicated to reduce the loss of kidney function in adult patients with primary IgAN, was approved by the Taiwan Food and Drug Administration, a Thursday filing with the Hong Kong Exchange said.
IgAN or immunoglobulin A nephropathy is a kidney disease which causes antibodies to build up in kidneys, which cause inflammation and damage to glomeruli, the small filters inside the kidneys.
Nefecon is an etiological treatment oral drug for IgAN and is fully approved by the US Food and Drug Administration.
The biopharmaceutical company's shares were down nearly 4% in recent trade.
Price (HKD): $33.60, Change: $-1.6, Percent Change: -4.41%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。